Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

2.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.7K
Clinical Trials01:16

Clinical Trials

6.6K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
6.6K
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.2K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.2K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

119
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
119
Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response01:15

Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response

41
Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
41
Hazard Ratio01:12

Hazard Ratio

85
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
85

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cerebral blood flow trajectories in paediatric sickle cell anaemia by age, region, and treatment associations.

British journal of haematology·2025
Same author

National Trends in Dexrazoxane and Cardiovascular Health Care Utilization for Children With Acute Myeloid Leukemia.

JAMA oncology·2025
Same author

Interactive Use of Cox Model-Predicted Survival Curves: An Application Using ACS10 Score and Age to Personalize Treatment of Pediatric AML.

JCO precision oncology·2025
Same author

Response to: Bayesian -reappraisal of ACNS0332 and ACNS0334 strengthens -subgroup treatment effects in high-risk pediatric group 3 medulloblastoma.

Neuro-oncology·2025
Same author

Imaging mediation analysis for longitudinal outcomes: a case study of childhood brain tumor survivorship.

Statistics and its interface·2025
Same author

Antibacterial activity and mechanism of Myxin from Lysobacter antibioticus against Xanthomonas fragariae.

Pest management science·2025

Related Experiment Video

Updated: Jun 3, 2025

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
00:04

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.6K

Interim Clinical Trial Data: Who Can See What, and When?

Susan S Ellenberg1, Yimei Li2

  • 1Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA. sellenbe@pennmedicine.upenn.edu.

Therapeutic Innovation & Regulatory Science
|January 8, 2025
PubMed
Summary

This study addresses challenges in randomized clinical trials by proposing methods to limit access to interim data. These approaches aim to maintain trial integrity while allowing necessary reviews for serious outcomes.

Keywords:
Accelerated ApprovalClinical TrialsConfidentialityData Monitoring CommitteeEndpoints

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.1K
In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

1.6K

Related Experiment Videos

Last Updated: Jun 3, 2025

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
00:04

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.6K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.1K
In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

1.6K

Area of Science:

  • Clinical Trials Methodology
  • Biostatistics
  • Regulatory Science

Background:

  • Traditionally, interim data in clinical trials for serious outcomes is kept confidential from investigators and sponsors.
  • Independent Data Monitoring Committees (DMCs) are responsible for regular interim data reviews.
  • Confidentiality challenges arise when sponsors or regulators need interim data access for trials, such as for accelerated approval pathways.

Purpose of the Study:

  • To propose novel approaches for minimizing interim data exposure in ongoing clinical trials.
  • To balance the need for data review with the principle of data inaccessibility.

Main Methods:

  • The paper outlines strategies for selective data sharing.
  • Focuses on methods to reduce the scope of accessible interim data.

Main Results:

  • Proposed approaches aim to reduce the risk of bias introduction.
  • Facilitates regulatory and sponsor reviews without compromising trial integrity.

Conclusions:

  • Implementing these methods can help preserve the integrity of randomized clinical trials.
  • Offers solutions for managing interim data access in critical public health research.